atrophy/protease

BACKGROUND OF THE INVENTION Morphological changes occur in the adult vertebrate brain both during normal learning and in various neuropathologies such as epilepsy and Alzheimer's disease (Refs. 1-3). These changes include neurodegeneration and more subtle remodeling of the cellular architecture, and

FIELD OF INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of

FIELD OF INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of

FIELD OF INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of

BACKGROUND OF THE INVENTION Apoptosis, or programmed cell death (PCD), is a genetically regulated mechanism with a central role in both metazoan development and homeostasis. (Raff, 1992; Steller, 1995). The cell death machinery is conserved throughout evolution (Vaux et al., 1994) and is composed of

FIELD OF INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of

1. FIELD OF THE INVENTION This invention relates to novel compositions comprising one or more of an acid protease enzyme and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically acceptable carrier, useful for treating or preventing abnormal skin conditions,

FIELD OF THE INVENTION This invention relates to novel compositions comprising one or more of an acid protease enzyme and an acidic buffer, the acidic buffer comprising an acidic buffering component that can reversibly disassociate hydrogen ions and has buffering capacity at pH values below that of

SEQUENCE LISTING A sequence listing submitted in computer readable format is hereby incorporated by reference. The computer readable file is named P224717sequencelist_ST25.txt, was created on Mar. 25, 2013, and contains 260 kilobytes. A supplementary sequence listing, submitted in computer readable

REFERENCES AND INCORPORATION BY REFERENCE Complete bibliographic citations for the references cited herein are contained in a section titled "REFERENCES," immediately preceding the claims. All of the documents listed in the "REFERENCES" section are incorporated herein. FIELD OF THE INVENTION The

This application is a U.S. national stage of International Application No. PCT/EP2006/061152 filed Mar. 29, 2006. FIELD OF THE INVENTION The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, to particular inhibitors of neurotrypsin, to the use of such

CROSS-REFERENCE TO RELATED APPLICATIONS This is a 371 National Stage Entry of International Application No. PCT/AT2007/000393, filed Aug. 16, 2007, which claims priority of Austrian Patent Application No. A 1376/2006, filed Aug. 16, 2006, the contents of which are incorporated herein in their

TECHNICAL FIELD This application relates to a novel use of cancer markers such as kallikreins, including prostate-specific antigen (PSA), as inhibitors of angiogenesis useful for treating angiogenesis-related diseases such as angiogenesis-dependent cancer. The invention further relates to novel

TECHNICAL FIELD This application relates to a novel use of cancer markers such as kallikreins, including prostate-specific antigen (PSA), as inhibitors of angiogenesis useful for treating angiogenesis-related diseases such as angiogenesis-dependent cancer. The invention further relates to novel

BACKGROUND OF THE INVENTION Evolution in mammals, reptiles, birds and fish has developed extraordinarily efficient musculoskeletal systems for generating and controlling motion. However, the musculoskeletal system is not only an efficient system for delivering useful mechanical energy and load